Experimental combo therapy aims to prevent leukemia relapse after transplant
NCT ID NCT06735690
First seen Nov 12, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-phase study tests whether giving specially engineered immune cells (CAR T cells) along with a vaccine is safe and feasible for people with high-risk acute lymphoblastic leukemia who have already received a stem cell transplant from a matched related donor. The CAR T cells are designed to target and kill leukemia cells, while the vaccine may help boost the immune response. The trial involves 15 participants and focuses on side effects and whether the treatment can be given as planned.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.